Oncimmune, a trademark in this day which associated with cancer diesis. Cancer which is a threat present from a long time ago in this earth. And to reduce its conscious effect different people try from their own field to help the affected ones. Like the name Oncimmune where a lot of words come together to fill it. Starting from a blood collection to supply medical apparatus to different test performed etc. In early cancer detection Oncimmune (USA) LLC, is an industry leader.
They have their prominent goal which is to be advanced early cancer detection to its possible greatest extent through the Early Cancer Detection Test by using a technology called autoantibody assay. To get succeed in this goal, they will strive to a number of steps. Like through the health care provider the test is available made to at-risk individuals.
Then by meeting the highest levels of laboratory testing standards and production and to ensure that they meet or exceed CLIA standards and requirements. As far as continue developing CDTTM in early for a wide range of cancers. Also the most vital one is to support research efforts by any university-based or others in technology of autoantibody as say at the University of Nottingham (UK) through The Centre of Excellence for Autoimmunity in Cancer (CEAC).
Not only that, they provide value-added services and information to the cancer advocacy groups or clients’ to promote and support prevention of cancer and its early detection.
Early detection is emphasized in case of a cancer patient is because it is evident that through randomized controlled trials of cervical, breast and colorectal cancers, an early detection can improves prognosis for a patients survival and also lowers mortality rates. In case of the other types of cancers like lung and gastric, the additional evidence from studies (nonrandomized) supports the suggestion that an early diagnosis may lead to improved chances of survival.